Medicare Part B spending on skin substitutes grew from about $400 million to nearly $3 billion per quarter in two years, surpassing $10 billion annually by the end of 2024, according to a September 2025 OIG data snapshot. That growth did not happen because wounds got bigger. It happened alongside billing patterns specific enough that payer and government analytics are now built to catch them directly: graft sizes that do not match wound size, application frequency that outruns clinical need, and site-of-service billing that pays substantially more for the same patient at home than in an office.
Graft Size Outliers
OIG's review found that a typical Part B enrollee received 82 units of skin substitute product in the third quarter of 2024, and OIG investigations have traced specific schemes to sales representatives ordering the largest graft size available regardless of the wound being treated, producing large grafts on small wounds and grafts billed against wounds that did not exist. One scheme alone generated more than $1.2 billion in false claims before the providers pled guilty. The pattern shows up without a site visit: a graft size that does not track the wound measurements already in the chart, often alongside a debridement code billed the same date whose own medical necessity the reviewer checks independently.
Application Frequency and Claim-Splitting
OIG separately flagged providers submitting multiple skin substitute claims for a single date of service, a pattern investigators tied to circumventing the claims system's cap on any single claim above $99,999.99. The consistent use of skin substitutes at a patient's first visit, before any conservative treatment was attempted, is its own flag, as is a provider specialty that does not fit the treatment, a neurologist or psychiatrist billing for skin substitutes among the examples OIG named. Local coverage determinations in many MAC jurisdictions separately cap how often a wound can receive an application in a given interval; billing beyond that cap is a flag independent of OIG's national findings.
The record that defends a graft-size or frequency outlier is the wound measurement and the conservative-treatment history already in the chart, not an explanation written after the audit letter arrives.
Site of Service: Home Care Versus the Office
Site of service is itself a billing variable analytics now track. In the third quarter of 2024, enrollees treated at home received 2.6 times more units on average than enrollees treated in a physician's office, 134 units versus 52, and the average cost per unit in the home setting was $1,718 against $1,099 in an office. The combined effect made the cost per enrollee four times higher for home-treated patients than for office-treated patients that same quarter. A practice billing substantially more skin substitute volume at home than its office-based peers is the comparison a payer's analytics run first.
What the Analytics Flag Actually Means for a Practice Under Review
None of these patterns by itself proves fraud. A severe wound can reasonably need a larger graft, a patient's condition can reasonably require more frequent application, and a homebound patient can reasonably need home-based care. What the record has to show is that the clinical facts, not the billing code, drove the decision, down to a signature log tying each application date to the clinician who actually performed it. The site-of-service documentation question goes deeper in Mobile Wound Care Practices Under Federal Review, and the billing-method questions behind a nurse practitioner's debridement claim are covered in Wound Care Nurse Practitioner Billing Compliance, which turn on whether the claim is billed under the nurse practitioner's own identifier or incident-to a supervising physician.
Why Early Legal Counsel Is Critical
It is critical that wound care providers promptly retain experienced healthcare defense counsel upon receiving an additional documentation request or a data-driven audit notice touching skin substitute billing. Early legal intervention can protect the practice's rights, ensure appropriate responses to government and payer requests, avoid inadvertent admissions about graft selection or application frequency, preserve relevant defenses, and allow counsel to communicate with investigators on the practice's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the practice to a larger extrapolated recoupment across its full lookback period.
How Health Law Alliance Can Help
Health Law Alliance defends wound care providers, including those using skin substitutes and debridement billing, through payer audits, UPIC reviews, and federal fraud investigations built on billing analytics.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
If your practice has received an audit notice involving skin substitute or wound care billing, contact us today for a free consultation through our Wound Care Audit Defense practice.
